Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)   MAY 2016 , Volume 10 , Number 3; Page(s) 51 To 55.
 
Paper: 

EFFICACY OF COMBINED PLASMAPHERESIS AND INTRAVENOUS IMMUNOGLOBULIN THERAPY IN KIDNEY TRANSPLANT PATIENTS WITH CHRONIC ANTIBODY-MEDIATED REJECTION

 
 
Author(s):  OGUZ EBRU GOK*, OKYAY GULAY ULUSAL, AKOGLU HADIM, MERHAMETSIZ OZGUR, YILDIRIM TOLGA, CANBAKAN BASOL, AYLI MEHMET DENIZ
 
* DEPARTMENT OF NEPHROLOGY, ANKARA DISKAPI YILDIRIM BEYAZIT EDUCATION AND RESEARCH HOSPITAL, ANKARA, TURKEY
 
Abstract: 

Introduction: Antibody-mediated rejections (AMRs) are critical clinical issues encountered in short- and long-term follow-up of kidney transplant patients. Whereas plasmapheresis is a mainstay treatment option in acute AMR cases, there is a paucity of data regarding its efficacy in management of chronic AMR. This report describes our experience addressing this issue.
Materials And Methods: We retrospectively investigated the data of 7 kidney transplant patients diagnosed with chronic AMR who were on 5 sessions of plasmapheresis (1 to 2 volume exchanges with fresh frozen plasma) on alternate days and 200 mg/kg of intravenous immunoglobulin after each session of plasmapheresis.
Results: At 6 months after the initiation of treatment, 6 patients experienced partially improved kidney function. One patient had no response and her kidney function progressively deteriorated.
Conclusions: Our preliminary results are encouraging for the combination of plasmapheresis and intravenous immunoglobulin as an adjunctive therapy for kidney transplant patients suffering from chronic AMR.

 
Keyword(s): CHRONIC ANTIBODY-MEDIATED REJECTION, IMMUNOGLOBULIN, KIDNEY TRANSPLANTATION, PLASMAPHERESIS
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 107
 
Latest on Blog
Enter SID Blog